• Vaccine Name: MDA-modified human apo B-100 peptide Vaccine
• Target Pathogen: Atherosclerosis
• Target Disease: Atherosclerosis, arteriosclerotic vascular disease (ASVD)
• Vaccine Ontology ID: VO_0004276
• Type: Subunit vaccine
• Status: Research
• Antigen: MDA-modified apo B-100 (Fredrikson et al., 2005).
• Adjuvant: aluminum hydroxide vaccine adjuvant
  • Adjuvant name: aluminum hydroxide vaccine adjuvant
  • VO adjuvant ID: VO_0000127
  • Description: Alum (aluminum hydroxide, Pierce) (Fredrikson et al., 2005).
• Immunization Route: Intramuscular injection (i.m.)

Mouse Response

• Host Strain: Male apo E0 mice on C57BL/6 background
• Vaccination Protocol: Mice (n = 8–10 per group) were given a first injection with a MDA modified peptide conjugated to the carrier or the carrier alone at 6 weeks of age and booster injections 3 and 5 weeks later. Each injection contained 50 mg of the MDA-modified peptide conjugated to 50mg of the carrier cBSA (cationized bovine serum albumin) dissolved in 0.083M sodium phosphate 0.9M NaCl pH 7.2, according to the manufacture’s protocol (No. 77652, Pierce, Rockford, IL, USA), and with Alum (aluminum hydroxide, Pierce) included in all injections as adjuvant. The mice were fed a cholesterol diet (0.15% cholesterol, 21% fat; Lactamin AB, Kimstad, Sweden) from the age of 10 weeks (Fredrikson et al., 2005).
• Efficacy: Immunization with fragment P45 reduced atherosclerosis with 48%; fragment P74with 31; whereas immunization with P240 had no effect (Fredrikson et al., 2005).